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Abstract
Cadherin cell adhesion molecules play an essential role in creating tight intercellular association and
their loss has been correlated with poor prognosis in human cancer. Mutational activation of
protein kinases and loss of cell adhesion occur together in human lung adenocarcinoma but how
these two pathways interconnect is only poorly understood. Mouse models of human lung
adenocarcinoma with oncogene expression targeted to subtypes of lung epithelial cells led to
formation of adenomas or adenocarcinomas that lacked metastatic potential. Conditional genetic
abrogation of epithelial tumour cell adhesion in mice with benign lung tumours induced by
oncogenic RAF kinase has been demonstrated to induce intratumourous vascularization
(angiogenic switch), progression to invasive adenocarcinoma and micrometastasis. Importantly,
breaking cell adhesion in benign oncogene-driven lung tumour cells activated β-catenin signalling
and induced the expression of several genes that are normally expressed in intestine rather than
the lung. I will discuss potential routes to nuclear β-catenin signalling in cancer and how nuclear β-
catenin may epigenetically alter the plasticity of tumour cells during malignant progression.
Background
Lung cancer has become the most prevalent neoplasm
throughout the world with 1,2 million deaths per year [1].
Non-small-cell lung cancer (NSCLC), with its main sub-
types adenocarcinoma, squamous cell and large-cell carci-
noma is the most frequent type (~80%) of lung cancer
with high metastatic potential and low cure rate. As is true
for most types of cancer, clinical onset of disease is noted
typically in people at an age over-fifties [2]. Since the inci-
dence of lung cancer was very low only five generations
ago, it is clear that changes in life style have caused the
surge of this disease [3]. Cigarette smoking is a major
cause of lung cancer, but about 25% of lung cancer cases
are found in non-smokers [4] and these may be attributa-
ble to passive smoking or other environmental causes.
Quite often, the primary lung tumour is inoperable at the
time of diagnosis because regional lymphatic and distant
organ metastases are already present [5]. Thus, progressed
disease state may in part explain the high mortality rates.
The knowledge of the cellular and genetic origin of lung
cancer is incomplete, because its detection in early stages
using computer tomography scans is only in its begin-
nings [6]. Significant progress has been made in identify-
ing genetic lesions in lung cancer by sequencing-based
mutation screening [7] and by characterizing copy-
number alterations [8]. Mouse models of the human dis-
ease offer the opportunity that the effects of oncogenes or
other genetic and epigenetic factors thought to underlie
the hallmarks of lung cancer can be studied and stages of
disease progression can presumably be identified [9]. Fur-
thermore, mouse modelling of human lung cancer pro-
vides a potentially powerful system for evaluation of
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novel therapeutic agents that may be clinically useful.
Finally, such mice will be valuable tools to identify the
origin of the cell(s) from which a lung tumour arises, the
cancer stem cell or tumour initiating cell [10,11].
Target cells for oncogenic transformation in the distal 
mouse lung
The major function of the lung is gas exchange. The epi-
thelial cells which line the tree of tubules and alveolar
units arise from progenitor cells present in the lung bud of
the ventral foregut endoderm. During embryonic devel-
opment, they form the epithelial lining of the conducting
airways and the distal vascularized sac-like structures. At
birth, fluid is resorbed from these sacs to expose a func-
tional gas exchange surface. The subsequent postnatal
maturation of the lung involves the formation of septa in
the terminal sacs (alveologenesis) leading to an expansion
of the gas exchange surface [12]. Thus, in the adult lung
distinct types of epithelial cells line the trachea, bronchi,
bronchioli and alveoli. The alveolar regions of the human
lung make up a surface of roughly 100 m2, whereas the
conducting airways cover less than 1% of this surface.
Early studies [13] on the nuclear incorporation of radio
labelled nucleotides and the maintenance of the label-
retaining cells in pulse-chase experiments showed that
epithelial cells of the mature rodent lung have a half-life
of about 100 days and that there could exist distinct types
of label-retaining cells – that may be stem cells – in differ-
ent anatomical regions of the adult lung. In line with this
notion, in case of injury or cell death caused by infections,
quiescent cells start to proliferate and replace the lost cells.
The topic of lung epithelial stem cells has been reviewed
recently elsewhere [14,15]. Alveolar type II pneumocytes
secrete a variety of pulmonary surfactant proteins (SP), for
example SP-C [16]. Type II cells are also the precursors of
type I cells which form the thin diffusion barrier impor-
tant for gas exchange in the alveolus (Figure 1). In mice,
SP-C expression is not restricted to type II cells, since rare
cells located at the bronchio-alveolar duct junction
(BADJ, Figure 1) co-express SP-C together with the Clara
cell antigen CC10, a marker specific for Clara cells,
another epithelial cell that normally lines the bronchi and
bronchioles [17]. The double-positive cell pool has been
shown to be resistant to naphthalene treatment which
destroys all other Clara cells lining the bronchus and the
terminal bronchioles. Furthermore, these cells have been
isolated based on their Sca1/CD34 phenotype and been
shown to be capable of self-renewal and differentiation in
vitro and thus have been called bronchio-alveolar stem
cells (BASCs, [18]). BASCs may however be only one of
several cell types that have stem cell properties and can
repair injured lung. Type II cells have also been shown to
re-enter the cell cycle and proliferate in radiation-induced
alveolar injury [19] and in bleomycin-induced destruc-
tion of type I and type II alveolar cells [18,20]. During
repair of alveolar damage, type II cells differentiate into
type I cells. It is notable, that type II alveolar cells prolifer-
ate in idiopathic pulmonary fibrosis, a proliferative lung
disease [21].
Epithelial cell types in the distal mouse lung Figure 1
Epithelial cell types in the distal mouse lung. Epithelial 
cell types present in the distal lung that might be target cells 
for oncogenic transformation are the bronchio-alveolar stem 
cell (BASC) that localizes to the   bronchio-alveolar duct 
junction (BADJ) and more differentiated cells with specific 
functions such as type II pneumocytes and Clara cells. The 
cuboidal alveolar type II cells as well as the columnar Clara 
cell may assume progenitor cell status in case of injury. 
Whether terminally differentiated type I pneumocytes can be 
recruited into tumours is not known.Cancer Cell International 2008, 8:7 http://www.cancerci.com/content/8/1/7
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Mutations in NSCLC and their corresponding mouse 
models
I will focus here on genes specifying components of the
classical mitogen activated protein kinase (MAPK) signal-
ling cascade which are among those most frequently over-
expressed, amplified or mutated in NSCLC (Figure 2).
Starting at the cell surface, overexpression of members of
the ErbB receptor family, most notably the epidermal
growth factor receptor (EGFR), and of some of its ligands,
such as EGF and TGF-α, has been observed [8,22]. In addi-
tion, mutations have been detected in NSCLC samples in
the kinase domain of the EGFR gene [23-25]. These muta-
tions endow the receptor with increased kinase activity
and lead to hyperactivation of downstream signalling cas-
cades. The EGFR active site mutants transform fibroblasts
and tracheobronchiolar epithelial cells [26]. Similar find-
ings have been reported for ERBB2 mutations [27] that
occur in approximately 2% of NSCLC [28]. Inducible
expression of the EGFR active site mutants in transgenic
mice has been achieved. Using the tetracycline-inducible
system where the transcriptional activator rtTA was
expressed under the CC10 promoter [29], conditional
expression of EGFR active site mutant proteins in adult
lungs led to adenocarcinoma formation [30,31].
RAS is a small GTP-binding protein tethered to the inner
cell membrane that couples growth factor receptor activa-
tion to the downstream RAF-MEK-ERK MAPK cascade
(Figure 3). Besides the RAF kinases, several other classes of
proteins have been implicated as effectors of RAS [32].
When activated by specific growth factors (for example
EGF), the fraction of RAS in the activated RAS-GTP form
increases at the expense of the inactive RAS-GDP form. A
high proportion of human cancers including those of the
lung carry activating point mutations in RAS (Figure 2)
[33]. These mutations result in the loss of the intrinsic
GTPase activity that is needed to return RAS to its inactive
GDP-bound state, leaving the mutated RAS permanently
active [34]. Several strains of mice with inducible alleles of
oncogenic K-RasG12D or K-RasG12V have been generated
[9]. A transcriptional stop element flanked by loxP sites
present in the targeted "floxed" allele prevented the
expression of the oncogene. The removal of the stop ele-
ment was achieved either "systemically" (in compound
mice harbouring also a Cre recombinase transgene) or
through infection of the lungs with recombinant adenovi-
rus expressing Cre recombinase. One of the mouse mod-
els allowed for the histochemical visualisation of the cells
that expressed the oncogenic K-RasG12V allele. Despite
widespread lung-targeted expression of RAS oncoprotein
upon activation of the oncogenic K-RasG12V allele, the
majority of the cells expressing the RAS oncoprotein did
not gain a proliferative advantage and only few adenomas
formed in the lung [35]. Since a substantial number of
cells in premalignant tumours underwent oncogene-
induced senescence, it has been proposed that this mech-
anism might limit tumour initiation and/or tumour pro-
gression from premalignant adenomas to malignant
adenocarcinomas [36]. None of the RAS mouse models
showed any evidence for metastatic spread of the
tumours. Notably, human lung cancer with K-RAS muta-
tions do not appear to progress, either [37].
RAF is a serine-threonine kinase that is activated down-
stream of RAS [38,39]. RAF activates the kinase MEK
(MAP kinase extracellular signal-regulated kinase) which
then activates ERK (extracellular signal-regulated kinase,
Figure 3). In mammals there exist three structurally simi-
Mutation frequency in NSCLC Figure 2
Mutation frequency in NSCLC. Frequency of activating 
point mutations and copy number amplifications found in 
NSCLC in genes specifying components of the classical 
mitogen activated protein kinase (MAPK) signaling cascade. 
The majority of alterations are point mutations that convert 
the proto-oncogene into a constitutive active oncogenic 
form. Frequencies for mutation-activated β-catenin 
(CTNNB1) and silencing of the promoter region of CDH1 
encoding E-Cadherin are shown. Data are derived from liter-
ature and the COSMIC database (version 35).Cancer Cell International 2008, 8:7 http://www.cancerci.com/content/8/1/7
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Regulation of cell adhesion by RAS/MAPK, RAS/PI3K/AKT and β-catenin signalling Figure 3
Regulation of cell adhesion by RAS/MAPK, RAS/PI3K/AKT and β-catenin signalling. In lung NSCLC, constitutive 
signalling is caused by mutational activation of components of the RAS/MAPK and/or RAS/PI3K/AKT pathways that endows 
tumour cells with enhanced proliferation and survival in the absence of a growth factor (GF). Loss of E-cadherin expression 
and disruption of a functional E-cadherin complex at the adherens junction are two events that occur in human lung cancers. 
Inducible disruption of the functional E-cadherin complex in a RAF oncogene-driven NSCLC mouse model led to the loss of 
adherens junction function and deadhesion of neighbouring tumour cells. In addition, nuclear β-catenin activity was instrumen-
tal for increased proliferation and survival of tumour cells, as well as the induction of angiogenic factors that facilitated the 
growth of a tumour vasculature (angiogenic switch) and changes in cell fate integrity (dysplasia).Cancer Cell International 2008, 8:7 http://www.cancerci.com/content/8/1/7
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lar RAF kinases, A-RAF, B-RAF and C-RAF. Inactivation of
the corresponding genes in mice indicates that the three
genes fulfil distinct roles [40]. Of the RAF family of pro-
tein kinases, B-RAF is the only member to be frequently
(~8%) activated by mutation in cancer [41]. Mutations in
A-RAF have not been found [42] and mutations in C-RAF
are rare in human cancers [43], but C-RAF is overex-
pressed in ovarian and pulmonary carcinomas [44,45].
The fact that B-RAF can be activated by a single amino acid
change, whereas C-RAF and A-RAF require two mutations
for oncogenic activation is thought to explain the differ-
ence in mutation frequency. Mice expressing in the lung
the most common oncogenic B-RAF mutation, B-
RAFV600E, have been established [46,47]. One model
employed a conditional targeted allele of oncogenic B-
RAFV600E containing a floxed transcriptional stop ele-
ment. Lungs infected with an adenovirus expressing Cre
recombinase developed benign tumours that grew rapidly
for about eight weeks and then showed signs of oncogene-
induced senescence (positive staining for p19ARF  and
Mec1; [46]). The second model used compound mice
with switchable (doxycycline-dependent) induction of B-
RAFV600E expression controlled by the CC10 promoter.
Administration of doxycycline for six weeks led to the for-
mation of adenomas, which regressed upon withdrawal of
doxycycline due to tumour cell apoptosis [47].
In another NSCLC model for oncogenic RAF, the SP-C
promoter-directed the expression of an oncogenic variant
of C-RAF, called C-RAF BXB [48]. The homeodomain con-
taining thyroid transcription factor 1, also called Nkx2.1,
controls the SP-C promoter and confers lung-specific gene
expression [49]. Importantly, NKX2.1 has been found to
be amplified in a significant number of lung adenocarci-
noma samples [8,50]. Conversely, lungs in Nkx2.1 defi-
cient mice have only two main bronchi and instead of an
epithelial tree, cystic structures with columnar cells form
and surfactant protein genes fail to be expressed [51]. The
SP-C promoter is active in the developing lung bud at
embryonic day E11 and in the subsequent stages of
embryonic lung development and postnatal lung matura-
tion, as well as in alveolar type II pneumocytes of adult
lung [52,53]. In the SP-C C-RAF BXB transgenic mouse,
lung development proceeds normally despite the fact that
the SP-C promoter is active during embryonic develop-
ment. Lung tumour initiation occurs in postnatal mice at
an age of about one week, but only a small fraction of
pneumocytes can be transformed. Several hundred ade-
nomas are forming in each lung, consisting of cuboidal,
SP-C expressing type II-like cells. Whether the rare ade-
noma initiation is due to the fact that only a small pool of
type II-like cells is susceptible to transformation or results
from mosaic C-RAF-BXB expression is currently unclear.
Neither impaired alveolar morphology nor function has
been noted in the vast majority of pneumocytes. The ade-
nomas grow continuously because a significant fraction of
tumour cells is proliferating [54]. The tumour cells did not
show overt signs of apoptosis [55,56]. Progression of the
adenomas towards adenocarcinomas was only observed
upon inactivation of p53 [57], similar to observations
made in lung epithelium expressing oncogenic B-RAF
[46]. No further progression towards malignancy, such as
intravasation into the lymphatic or blood vasculature and
outgrowth of organ metastasis has been observed [54],
not even after a period of more than 12 months of contin-
uous lung tumour growth [54]. Thus, the adenomas of the
SP-C C-RAF BXB model contain proliferating and surviv-
ing epithelial tumour cells, making the model suitable to
identify tumour progression factors in lung tumourigene-
sis. Importantly, the adenomas resemble atypical adeno-
matomous hyperplasia in human lung. Such lesions have
been detected incidentally in resected human lung [58]
and more recently on a larger scale as a result of computer
tomography screening [6]. In sum, mutations along the
growth factor receptor kinase-RAS-RAF axis together
account for more than 50% of all NSCLC cases. They
appear to be functional equivalent as they are nonoverlap-
ping underscoring the important role of this pathway in
human lung cancer (Figure 3).
Increased growth factor receptor or RAS signalling not
only activates RAF but in addition phosphoinositide-3-
kinase (PI3K, Figure 3). PI3K family proteins catalyze the
phosphorylation of the 3-position of the inositol ring in
phosphoinositide substrates [59]. These phospholipid
second messengers recruit the serine/threonine protein
kinase B (PKB, also known as AKT) to the cell membrane
where its activation by other kinases occurs [60]. Active
AKT phosphorylates a variety of proteins that mediate
increased cell proliferation and cell survival [60]. Aberrant
activation of the PI3K/AKT pathway has been implicated
in lung cancer progression [61-63]. Conversely, the PI3K
antagonistic enzyme PTEN (phosphatase and tensin
homolog) is lost by mutations, deletions or promoter
methylation at high frequency in human lung cancer [63-
65]. Mice with K-RasG12D  oncogene activation with a
PI3K unable to interact with RAS only formed premalig-
nant lesions but no macroscopic lung tumours [66].
Breaking the cadherin adhesion complex in RAF-driven 
adenomas
In haematoxylin-eosin stained tissue sections of adeno-
mas from SP-C C-RAF BXB mice, neighbouring tumour
cells seemed to be in direct contact and therefore probably
maintained the expression of adhesion molecules. Immu-
nostaining revealed that E-cadherin was indeed expressed
uniformly in the adenomas of SP-C C-RAF BXB mice [54].
E-cadherin is the dominant cadherin in epithelial tissues
[67]. The extracellular part of E-cadherin forms calcium-
dependent homophilic dimers thus mediating cell-to-cellCancer Cell International 2008, 8:7 http://www.cancerci.com/content/8/1/7
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adhesion and joining neighbouring epithelial cells. The
cytoplasmic domain of E-cadherin is organized in a heter-
omeric complex with β-catenin bound directly to a con-
served sequence in the distal part of its cytoplasmic
domain and α-catenin, a relative of vinculin, bound to the
N-terminus of β-catenin. E-cadherin and β-catenin are
phosphoproteins and phosphorylation acts as a biochem-
ical switch to regulate complex formation at adherens
junctions and shuttling between subcellular destinations
(see below). Indeed, mutational analysis of a serine-rich
catenin-binding domain of cadherin revealed that serine
phosphorylation is important for E-cadherin-catenin
interaction [68]. It appears that soon after translation, β-
catenin – α-catenin dimers form a complex with cadherin
before being transported to the cell surface [69]. This core
complex at the adherens junction (Figure 4) forms a
dynamic link to the actin cytoskeleton [70,71]. Other
molecules have also been found to become associated
with the core complex. These include p120-catenin, which
interacts directly with the membrane-proximal region of
the cadherin cytoplasmic domain and may assemble non-
receptor tyrosine kinases such as Fyn, Yes and Fer to the
complex [72,73]. In addition, the tyrosine phosphatase
PTP1B may be recruited to p120-catenin, at least in
fibroblasts and neural cells which express N-cadherin
instead of E-cadherin [74].
Regulation of adherens junction and β-catenin stability Figure 4
Regulation of adherens junction and β-catenin stability. A, Localization of β-catenin at the adherens junction occurs in 
a complex with E-cadherin and α-catenin. β-catenin is also present in the β-catenin-destruction complex where it is being 
degraded in the absence of Wnt ligand. B, Growth factor (GF) as well as oncogene mediated activation of kinases can phospho-
rylate two conserved tyrosine residues in the N- or C-terminus of β-catenin, leading to a disruption of the adherens complex 
and formation of a nuclear β-catenin complex. Once in the nucleus, β-catenin can replace co-repressors from TCF/LEF and 
thereby form activating transcriptional complexes. Activation of Wnt results in the stabilization of β-catenin and its nuclear 
accumulation where Wnt target genes are turned on (see text for details).Cancer Cell International 2008, 8:7 http://www.cancerci.com/content/8/1/7
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β-catenin has a second life in the canonical Wnt (wing-
less/int) cascade [75]. In the absence of a Wnt ligand, it is
present in the "β-catenin-destruction complex", an assem-
bly of proteins that includes the scaffolding protein Axin,
adenomatous polyposis coli (APC) protein, casein kinase
Iα and glycogen synthase kinase-3 (GSK-3, [76]). GSK-3
phosphorylates β-catenin at serine/threonine residues N-
terminal to the first armadillo repeat (Figure 4A, and see
below). The phosphorylated motif allows the binding of
a component of the E3 ubiquitin ligase, followed by ubiq-
uitination and degradation by the proteasome. When Wnt
signalling becomes activated, β-catenin escapes the degra-
dation complex and migrates to the cell nucleus (Figure
4B). Since β-catenin does not bind to DNA itself, it has to
form a complex with TCF/LEF (T-cell factor/lymphoid
enhancer factor) transcription factors [77]. These com-
plexes assemble components of the general transcription
machinery and proteins involved in chromatin modifica-
tion to induce the expression of a specific subset of gene
targets which mainly determine cell proliferation and cell
fate [78]. These include cyclin D1 and c-Myc which are up-
regulated in colon cancers [78]. c-Myc is a key mediator of
activated Wnt signalling in murine intestinal cancer [79].
GSK-3 family proteins (GSK-3α and GSK-3β) are constitu-
tively active in resting cells. The transcription factor Snail
has been identified as one target of GSK-3 leading to the
nuclear export and destruction of Snail by the proteasome
[80]. GSK-3 activity is suppressed in response to external
signals and involves AKT-mediated phosphorylation at an
N-terminal motif [81]. Inactivation of GSK-3β by phos-
phorylation of the N-terminal serine might be involved in
tumour progression because it leads to increased levels of
c-Myc (cellular Myelocytomatosis, also called MYC,
encoded by the MYC gene, [82]; see below). Knock-in
mice where the N-terminally serines of GSK3 proteins
were replaced by alanines had no defects in Wnt signalling
indicating that GSK-3 activity in the Wnt pathway is regu-
lated in a manner distinct from phosphorylation of the N-
terminal serine that may involve disassembly of the β-cat-
enin-destruction complex [83,84]. Another consequence
of GSK-3 inactivation is that Snail will accumulate in the
nucleus and repress E-cadherin expression (Figure 4B).
We addressed the functional consequences of weakening
or destroying cell-to-cell adhesion in the adenomas of SP-
C C-RAF BXB mice using two different genetic approaches,
conditional ablation of the Cdh1  g e n e  i n  m i c e  w i t h  a
"floxed" Cdh1 gene [85] or switchable expression of dom-
inant negative E-cadherin. As expected, the ablation of
functional E-cadherin caused deadhesion among tumour
cells [54]. In addition, in a fraction of tumour cells,
nuclear  β-catenin was observed, indicating that upon
removal of E-cadherin, β-catenin was not completely
destroyed but transported to the nucleus. Thus, the release
of β-catenin from the cadherin complex not only affected
the integrity and function of the adhesion complex, but
may also have made it available for signalling in the
nucleus. This observation is in line with a previous inves-
tigation in non-timorous cells, where the formation of a
transcriptional  β-catenin complex has been observed
upon loss of E-cadherin [86].
Increased tumour cell proliferation was observed in vivo,
in line with the up-regulation of cyclin D1 and c-Myc in
tumour cells 36 hours after induction of dominant nega-
tive E-cadherin [54]. After induction of dominant negative
E-cadherin or inactivation of the Cdh1 gene, massive for-
mation of blood and lymph vessels, termed the "ang-
iogenic switch" [87] was observed in the adenomas [54].
Vascular endothelial growth factors A and C were identi-
fied as β-catenin target genes in vivo and in NSCLC
tumour cells [54]. The finding that vessel induction by
dominant negative E-cadherin was reversible in the early
phase of induction, but was no longer reversible after
long-term ablation of E-cadherin may be explained by the
eventual acquisition of a tumour vessel signature [88].
Vascularized tumours developed invasive fronts and gave
rise to micrometastasis in thoracic lymph nodes and bone
marrow. It is notable that the presence of micrometastases
in lymph nodes in lung adenocarcinoma patients corre-
lates with poorer outcomes as compared to those lacking
detectable micrometastases [89]. Progression towards
malignancy upon ablation of E-cadherin in epithelial
tumour cells was not only observed in RAF-driven lung
tumourigenesis [54] but also in a mouse breast cancer
model with epithelium-specific inactivation of p53 [90].
Combined loss of E-cadherin and p53 led to accelerated
development of invasive and metastatic mammary carci-
nomas [90].
Many roads to nuclear β-catenin signalling in cancer
Frequent mutational activation of Wnt/β-catenin signal-
ling has been observed in various types of human cancers
[91]. With respect to genes specifying the adhesion com-
plex, mutations in E-cadherin (CDH1) have been found
in gastric and colon cancer but have not yet been reported
in lung cancer. The most frequent colorectal cancer-asso-
ciated genetic lesions are loss-of-function mutations in
the APC gene and they result in sustained β-catenin signal-
ling [91]. Activating mutations have also been identified
in the CTNNB1 gene, which encodes β-catenin, in colon
cancer cells [92] as well as in melanoma cell lines [93]. In
addition, deletions in exon 3 of CTNNB1  have been
detected in colorectal carcinomas and transcripts lacking
exon 3 are translated into a stabilized β-catenin with dom-
inant nuclear β-catenin signalling [94,95]. Colon-
restricted conditional expression of stabilized β-catenin
mutant in transgenic mice led to the formation of adeno-
matous intestinal polyps and colon microadenomas [96].
In human lung cancer, mutations have not been reportedCancer Cell International 2008, 8:7 http://www.cancerci.com/content/8/1/7
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for APC and are rare in CTNNB1 (3%) [97]. Activation of
Wnt signalling upstream of β-catenin has been observed
in a low number of lung cancer samples [98]. Whether
nuclear expression of β-catenin correlates with poor or
better prognosis in NSCLC is unclear [98].
I will now discuss alternative mechanisms that may result
in nuclear β-catenin signalling in cancer cells in the
absence of overexpressed Wnt ligands or mutational acti-
vation in the canonical Wnt/β-catenin signalling cascade.
Repression of CDH1  expression by epigenetic mecha-
nisms might lead to a loss of E-cadherin function in the
absence of CDH1  loss-of-function mutations. Aberrant
methylation of normally unmethylated CpG islands in
the promoter regions of genes has been correlated with
transcriptional inactivation of several genes in human
cancer. Silencing of E-cadherin expression by promoter
CpG methylation was found in a variety of human epithe-
lial carcinoma cell lines [99]. In primary NSCLC cancers
CpG island methylation was detected at a frequency of
18% with methylation-specific PCR [100]. Secondly, tran-
scription factor-mediated suppression of E-cadherin
expression might be at play. Indeed, Twist, a transcription
factor that suppresses E-cadherin expression and cell-to-
cell adhesion, has been found to be up-regulated in breast
cancer [101]. The contribution of Twist towards malig-
nancy may use as an additional mechanism the induction
of miR-10b in breast cancer cells [102]. miR-10b belongs
to the class of regulatory small cellular RNAs, termed
microRNA (miRNA), that act as mediators of the RNA
interference pathway. Twist-induced miR-10b, and miR-
10b was found to inhibit the expression of the HOXD10
protein, permitting the expression of the pro-metastatic
gene product, RHOC [102].
As a further possibility we have to consider that β-catenin
may be released by phosphorylation from complexes at
the membrane and subsequently enter the nuclear signal-
ling pool. The three-dimensional structure of β-catenin
and the structure of the cadherin/β-catenin complex have
been elucidated [103,104]. β-catenin has 12 armadillo
repeats; each repeat is composed of three α-helices. The
binding interface of β-catenin with E-cadherin involves
armadillo repeats 5–12 whereas the interaction of β-cat-
enin with the DNA binding factor TCF-4 uses armadillo
repeats 3–8. Therefore, some flanking armadillo repeats of
β-catenin would be suitable for posttranslational modifi-
cations that may disrupt specifically E-cadherin or α-cat-
enin binding without ablating the interaction with TCF.
As detailed below, phosphorylation of β-catenin at two
critical tyrosine residues, tyrosine-142 and tyrosine-654,
has been shown to disrupt the E-cadherin/β-catenin adhe-
sion complex with concomitant β-catenin nuclear activity
(Figure 4). Since both modifications lie outside the inter-
action domain with LEF/TCFs, complex stability of β-cat-
enin with LEF/TCFs would not be affected by
phosphorylation.
Cell surface transmembrane tyrosine kinase receptors
modulate the adhesion complex by phosphorylation, as
demonstrated for the EGFR [105]. This work showed that
the EGFR is associated with the E-cadherin-β-catenin
adhesion complex and that the receptor can phosphor-
ylate β-catenin in vitro and in three epithelial cell lines.
Furthermore, an association of β-catenin with receptor
ERBB2 together with phosphorylation of β-catenin has
been shown in gastric cancer cell lines [106-108]. Acti-
vated RAS has been shown to induce tyrosine phosphor-
ylation of β-catenin leading to disruption of adherens
junctions in an epithelial cell line [109]. In transgenic
mice, intestinal expression of an oncogenic K-RasG12V
allele in conjunction with a loss-of-function allele of APC
was shown to increase nuclear β-catenin signalling [110].
This combination of genes led to increased intestinal
tumour initiation and accelerated tumour progression
[110]. Activation of the tyrosine kinase Src in epithelial
MDCK (Madin-Darby canine kidney) cells impaired cell
adherens junction function via phosphorylation of β-cat-
enin [111]. Src has been shown to phosphorylate β-cat-
enin on tyrosine-654 in vitro and evidence was provided
that this phosphorylation is important for the disruption
of the E-cadherin/β-catenin complex in a colorectal cell
line [112]. Furthermore, tyrosine-654 phosphorylation in
vitro induced the formation of a β-catenin complex with
the nuclear TATA binding protein [113]. Using a Src
kinase inhibitor, tyrosine phosphorylation of β-catenin
was blocked and expression of β-catenin target genes was
reduced in a colorectal cancer cell line [114]. In addition,
cell-to-cell adhesion was restored in the presence of the
Src kinase inhibitor, whereas cell migration was strongly
reduced [114]. In fibroblast cells, overexpression of
another tyrosine kinase, Fer led to a disruption of adher-
ens junction complexes [115].
Tyrosine-142 is present in the first armadillo repeat which
overlaps with the α-catenin binding region of β-catenin.
Phosphorylation of this residue induced the dissociation
of α-catenin from the E-cadherin/β-catenin complex with
concomitant loss of cell aggregation [116]. Tyrosine-142
is phosphorylated by Fyn, Fer and Met, the tyrosine kinase
cell surface receptor for hepatocyte growth factor (HGF).
Stimulation of the Met receptor in conjunction with over-
expression of Bcl 9-2, an adaptor protein that links β-cat-
enin to transcriptional coactivators, in epithelial MDCK
cells did not only disrupt cell-to-cell adhesion but pulled
β-catenin from an adhesion complex into a nuclear com-
plex with Bcl 9-2. Thus, phosphorylation of tyrosine-142
weakened α-catenin binding to β-catenin in favour of a
nuclear β-catenin complex with Bcl 9-2 [117]. In primary
hepatocytes, where a significant fraction of β-catenin isCancer Cell International 2008, 8:7 http://www.cancerci.com/content/8/1/7
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bound to Met, HGF induced nuclear translocation of β-
catenin [118]. We also have to consider that trimeric Met/
E-cadherin/β-catenin complexes may exist in cancer cells
[119,120] and that Met activation may occur in a signifi-
cant fraction of lung adenocarcinoma samples [121]. In
NSCLC, intronic mutations occur in MET [122]. They lead
to the expression of a receptor with a deleted juxtamem-
brane domain with sustained kinase activity after HGF
stimulation [122]. Another possibility that might switch
β-catenin from an adhesive into a signalling factor is a
conformational change in the C-terminus of β-catenin
[123]. In sum it is clear that there are additional routes to
nuclear β-catenin signalling, parallel to the Wnt pathway.
They operate by weakening the association of E-cadherin
with β-catenin in the adhesion complex, using a variety of
mechanisms and thus make β-catenin available as a
nuclear signalling partner in cancer cells, including those
present in lung adenocarcinoma. Further studies are
required to define at what stage of tumourigenesis any of
the proposed mechanisms are relevant.
β-catenin signalling and the induction of dysplasia
Why did the disseminated tumour cells forming a
micrometastasis in compound mice with oncogenic RAF
and disrupted adherens junctions fail to colonize and
grow into a macrometastasis? One obvious explanation
may be the failure of the micrometastasis to acquire a
"metastasis virulence gene" that would allow for coloniza-
tion in the new tissue [124]. A second possibility comes
from observations in several human cancers showing that
loss of E-cadherin function is accompanied by the expres-
sion of other cadherin family members, termed "cadherin
switch" [125]. According to this model, tumour cells
forming a micrometastasis have to re-establish adhesion
at the new organ site in order to grow. The conditional
transient re-expression of E-cadherin at the stage of
micrometastasis should allow testing this hypothesis. A
third scenario may be inappropriate β-catenin activity.
When systemic, long-term activation of β-catenin signal-
ling was induced in six week-old SP-C C-RAF BXB mice
with lung adenomas via the expression of dominant neg-
ative E-cadherin, RT-PCR analysis of tumour cell mRNA
revealed the expression of genes (Cdx1, Atoh1) that are
normally expressed in the intestine indicating that an epi-
genetically-driven change in cell fate had occurred [54]. As
it is not clear, whether the lung cells changed morpholog-
ically into intestine cells or acquired a broader range of
pluripotency or self renewal activity, I shall call this form
of epigenetic plasticity dysplasia [126]. During embryonic
and postnatal organ development and cell differentiation,
cell fate programmes are altered in response to extracellu-
lar cues. Under physiologic conditions, these cues (type
and dose of signalling molecules) are provided by neigh-
bouring cells or through the circulation. The cues manifest
in the epigenetic regulation of gene expression by herita-
ble modification of the DNA (principally methylation of
CpG dinucleotides) and through altering chromatin. His-
tone proteins function as building blocks that package the
DNA into nucleosomes and distinct histone modifica-
tions form a "histone code" [127]. Modifications that con-
dense chromatin, modify the access of transcription
factors to DNA or recruit other complexes such as the
Polycomb complex to chromatin, occur during develop-
ment as well as in stem cells and cancer [128,129]. The
modifications serve as cell fate-specific marks. They are
generally passed on unchanged from one cell to its daugh-
ter cells and secure the faithful expression of differentia-
tion-associated genes.
Therefore, it appeared that there may be no way back for
a differentiated committed cell to an earlier fate after it has
lost its pluripotent capacity. However, there are examples
for transdifferentiation, the transformation of one differ-
entiated cell into another [126]. Furthermore, epigenetic
changes are reversible and have been experimentally
induced by somatic cell nuclear transfer and cell fusion,
and more recently via combined expression of four spe-
cific transcription factors, also termed "magic brew"
[130]. The four factors (Oct3/4, Sox2, Klf4 and c-Myc,
with c-Myc being an oncogene) reprogrammed mouse
fibroblasts into induced pluripotent stem (iPS) cells that
resemble embryonic stem cells in terms of morphology
[131]. The achievement of bona fide reprogramming
towards pluripotency was proven, since the iPS cells, after
injection into early embryos, differentiated into all nor-
mal adult cell types [132-134]. While the first report [131]
used drug selectable markers driven by promoters that are
active in embryonic stem cells for the isolation of rare iPS
cells, morphology alone can also be used to detect iPS
clones [135]. It also appears that two of the factors, Myc
and Klf-4 increase the frequency of reprogramming and
are not strictly necessary [135,136].
The MYC proto-oncogenes are essential activators of cell
proliferation and have emerged as some of the genes most
commonly deregulated in cancer [137]. Activation of
MYC genes in human cancer occurs by amplification or
loss of transcriptional control, which results in MYC pro-
tein overexpression. In NSCLC, MYC gene copy number is
found to be amplified in a fraction of specimen [8]. The
up-regulation of c-Myc at the post-transcriptional level
also appears to be of instrumental importance for c-Myc
to promote tumour progression [138]. The half-life of c-
Myc is controlled by a number of sequential, reversible
phosphorylations on two conserved residues, serine-58
and serine-62. In response to MAPK signalling, c-Myc is
phosphorylated on serine-62; parallel activation of PI3K/
AKT leads to the inactivation of GSK3, with threonine-58
remaining unphosphorylated [82]. Active GSK-3 however
can phosphorylate c-Myc on threonine-58 if serine-62 isCancer Cell International 2008, 8:7 http://www.cancerci.com/content/8/1/7
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phosphorylated which subsequently may lead to its deg-
radation through the activity and co-operation of other
enzymes such as prolyl isomerase 1 and protein phos-
phatase 2A [138].
In transgenic mice expressing Nmyc from the SP-C pro-
moter progenitor cells in the developing distal lung
expanded in numbers and their differentiation was
blocked leading to disturbed lung function and perinatal
death [53]. SP-C promoter-directed overexpression of c-
Myc in transgenic mice did not disturb lung development
and induced tumour formation in the lung only after long
latency [139], suggesting that a second hit, presumably
the mutational activation of an oncogene, may be needed
for tumour initiation. In contrast, conditional Myc overex-
pression in other tissues such as the haematopoietic sys-
tem or the liver induced carcinomas with short latencies
[140,141]. Importantly, abrogation of Myc expression
caused tumour regression arguing against additional
mutational events during carcinoma formation. When
hepatocellular carcinoma cells or distant lung metastases
derived from the carcinomas were transplanted under the
skin of SCID mice, tumours engrafted in the recipient ani-
mals. The tumours regressed after abrogation of Myc
expression and the residual scar tissue under the skin con-
tained differentiated cells resembling hepatic lobules
[141], indicating that the transplanted metastatic cells
could regain their differentiated phenotype.
According to a classical model, c-Myc is a basic-helix-
loop-helix zipper transcription factor that dimerizes with
Max leading to the activation of genes that contain bind-
ing sites for Myc-Max complexes. The identification of
thousands of putative c-Myc target genes [142], the find-
ing that about half of all DNA sites binding c-Myc were
intergenic (>10 kb away from transcriptional start sites
[143], and the finding that c-Myc promotes DNA replica-
tion through a non-transcriptional mechanism with sub-
sequent DNA damage [144] indicate that the classical
model does not fully explain tumourigenic c-Myc func-
tion. Conditional disruption of N-Myc in distal lung epi-
thelial cells inhibited distal lung proliferation and
induced premature differentiation indicating that it is
required for maintaining a distal population of undiffer-
entiated, proliferating progenitor cells [53].
A form of epigenetic plasticity similar to that noted in
adult mice with oncogenic RAF-driven lung tumours with
disruption of adherens junctions and nuclear β-catenin
signalling [54] had been observed before in embryonic
lung epithelium in transgenic mice with SP-C promoter-
directed expression of a constitutively active fusion pro-
tein of β-catenin and the transcription factor Lef1 [145].
These lungs lacked differentiated lung cell types and
showed a hyperproliferative epithelium expressing Cdx1,
Atoh1 and other genes normally expressed in intestinal
epithelium. Another example of reprogramming has been
observed upon introduction of activated β-catenin into
either the common lymphoid or common myeloid pro-
genitors [146]. Multipotential cells giving rise to both
lymphoid and myeloid offspring were generated but
apparently only single-step reversion in the developmen-
tal hierarchy had occurred, because upon grafting into
irradiated mice, no full reconstitution was observed [146].
Therefore, the question arises whether step-wise reversion
in epigenetically controlled developmental programmes
of gene expression may contribute to malignancy. Indeed,
it has been proposed, that tumour-restricted "recapitula-
tion" of signatures that are normally restricted to embry-
onic development might contribute to neoplastic
progression [147,148]. In line with this hypothesis, Wnt
signalling has been proposed to increase the self-renewal
capacity of haematopoietic stem cells [149]. However,
two groups have recently reported [150,151] that induci-
ble overexpression of a stabilized β-catenin increased the
proliferation of haematopoietic cells as expected but led
to an exhaustion of functional haematopoietic stem cell
potency. Mechanistically, the loss of a haematopoietic
stem cell signature (HoxB4, Pu.1, Bmi-1 expression) was
observed. Whether a similar stem cell-suppressive action
is at play in lung tumours with oncogenic C-RAF and
dominant-negative E-cadherin expression has to be deter-
mined.
Conclusion
Two recent studies have evaluated the consequences of the
loss of E-cadherin in conjunction with either oncogenic
RAF kinase expression or loss of p53 for malignant pro-
gression of epithelial tumours. The investigation of the
breast cancer model revealed that combined loss of E-cad-
herin and p53 in mammary epithelial cells induced
metastastic carcinoma that resembles invasive lobular car-
cinoma. In the lung NSCLC model, disruption of E-cad-
herin led to vascularized tumours that grew rapidly and
gave rise to micrometastasis. Nuclear β-catenin signalling
was instrumental for up-regulation of vascular endothe-
lial growth factor expression and epigenetic plasticity.
Published data are being reviewed on how receptor and
non-receptor kinases impinge on the stability of the adhe-
rens junction complex. Evidence suggests that kinases
may modulate nuclear β-catenin signalling. In a coopera-
tive manner, kinases and nuclear β-catenin may be instru-
mental for the expression of gene targets in the lung which
in turn is involved in malignant progression. I finally dis-
cuss what mechanisms may block the step from microme-
tastasis to macrometastasis and how E-cadherin function,
together with oncogenic and nuclear β-catenin signalling
might control this important step of malignancy.Cancer Cell International 2008, 8:7 http://www.cancerci.com/content/8/1/7
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